CompletedPhase 2NCT01479972

Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa

Studying Tuberculosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Serum Life Science Europe GmbH
Principal Investigator
Mark Cotton, MD, Professor
Children's Infectious Diseases Clinical Research Unit (KID-CRU), Tygerberg, South Africa
Intervention
VPM1002(biological)
Enrollment
48 enrolled
Eligibility
All sexes
Timeline
2011 – 2012

Study locations (1)

Collaborators

Children's Infectious Diseases Clinical Research Unit (KID-CRU), South Africa · Triclinium Johannesburg, South Africa · University of Stellenbosch · HJ-CTC George, South Africa

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01479972 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis →

← Back to all trials